Share on LinkedInShare on LinkedIn

ARTICLE · 17 FEBRUARY 2022

"Unofficial" CN Orange Book User Guide For Pharmaceutical Patents (Dec 2021 Ver.)

In the US, the Orange Book is a publication from the US FDA that identifies drug products with marketing approval from the FDA and related patent and exclusivity information.

ChinaIntellectual Property

In the US, the Orange Book is a publication from the US FDA that identifies drug products with marketing approval from the FDA and related patent and exclusivity information. Information in the Orange Book could be used in actions under the Hatch-Waxman Act, which allows a patentee to file an artificial act of infringement that allows the drug innovator to file suit before the generic drug is commercialized, such that the drug marketing approval process of the generic drug at the US FDA could be suspended.

China is required to introduce a similar system under the Phase-I Trade Agreements signed with the US in January 2020. I have been following this since then, and have several articles and posts on this topic. Recently, this "CN Orange Book" (official name: China listed drugs patent information registration platform) has become officially online on 29 June 2021, with many developments thereafter, and I have received many questions on how to use this. This motivates

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from